Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial

BACKGROUND: EGFR‐tyrosine kinase inhibitors (TKIs) combined with TS‐1 might overcome EGFR‐TKI resistance, which has been indicated by several preclinical studies. We investigated the synergistic efficacy and safety of the combination therapy of EGFR‐TKIs and TS‐1 in non‐small cell lung cancer (NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lu, Yang, Sheng, Liu, Yutao, Li, Junling, Hu, Xingsheng, Wang, Yalei, Zhang, Yan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983211/
https://www.ncbi.nlm.nih.gov/pubmed/29655198
http://dx.doi.org/10.1111/1759-7714.12632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983211/
https://www.ncbi.nlm.nih.gov/pubmed/29655198
http://dx.doi.org/10.1111/1759-7714.12632

Ejemplares similares